Innovative Medicines Canada Responds to the Release of Revised PMPRB Guidelines

OTTAWA / ACCESSWIRE / June 19, 2020 / Innovative Medicines Canada released the following statement today in response to the release of revised PMPRB pricing guidelines:

“We have just received the revised Guidelines and we will be examining them closely, in consultation with our members, after which we will be in a position to comment in more detail.

“We remain deeply concerned about the impact the amended Patented Medicines Regulations will have on Canadians’ access to affordable, innovative medicines, and on the country’s ability to attract investment to our life-sciences sector. As the COVID-19 crisis has shown, Canada’s innovative medicines companies are vital to the health and well-being of all Canadians, and we need a regulatory environment that encourages it to grow and thrive. We look forward to actively participating in the 30-day consultation process.

“It is not too late to find a solution that will prevent negative consequences of the amended regulations, while still allowing the Federal government to meet their public policy objectives.”

About Innovative Medicines Canada

Learn more about how our member companies are contributing to the fight against COVID-19.

Innovative Medicines Canada is the national voice of Canada’s innovative pharmaceutical industry. We advocate for policies that enable the discovery, development and commercialization of innovative medicines and vaccines that improve the lives of all Canadians. We support our members’ commitment to being valued partners in the Canadian healthcare system.

For further information:

Sarah Dion-Marquis
Director, Media and Public Relations
Telephone: 613-769-6510
E-mail: sdmarquis@imc-mnc.ca

SOURCE: Innovative Medicines Canada’s Health Research Foundation (HRF)

View source version on accesswire.com:
https://www.accesswire.com/594529/Innovative-Medicines-Canada-Responds-to-the-Release-of-Revised-PMPRB-Guidelines

Staff

Recent Posts

Syngene launches platform for rapid, enhanced protein production

The new proprietary cell line development platform combines a robust cell line, transposon technology with…

10 mins ago

Stanford Blood Donor Center Chooses the HemoFlow 500 and HemoVue Cloud Service to Streamline Its Whole Blood Collection Operations

GRASS VALLEY, CA / ACCESSWIRE / June 4, 2024 / Applied Science, the worldwide leader…

3 hours ago

KORU Medical Systems Announces a New Feasibility Study with a Commercialized Oncology Biologic

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading…

6 hours ago

KORU Medical Systems Announces a New Feasibility Study with a Commercialized Oncology Biologic

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading…

6 hours ago

AffableBPM names Greg Chavers as new Chief Revenue & Sales Officer to drive innovation in healthcare automation

SEATTLE, June 4, 2024 /PRNewswire/ -- AffableBPM, a leader in AI-powered business process automation for…

6 hours ago